Nucleix, an Israeli medtech startup that offers a liquid biopsy which it says can detect cancer early, secured an additional $22 million in funding, as an extension to the previously announced $55 million financing, bringing the total capital raised in 2021 to $77 million.
Nucleix is just one of a number of Israeli medtech startups working to help cure, or at least defeat, cancer.
Israeli medtech startup Ibex Medical Analytics uses artificial intelligence (AI) in cancer diagnosis. Last March the company raised $38 million in a Series B financing round. Ibex’s main product is Galen. The company boasts that the Galen platform demonstrated “outstanding outcomes in clinical studies and helps pathologists reduce diagnostic error-rate, obtain 100% quality control and enable a more efficient workflow.” The Ibex Galen Breast and the CE-marked Galen Prostate are the first-ever AI-powered cancer diagnostics solutions used in routine clinical practice in pathology labs.
In September, Novellus, an Israeli clinical-stage biotechnology company focused on precision oncology (treatment for cancer) raised $57 million in a Series C financing round. Novellus focuses on the development of compounds for established oncogene drivers with a high incidence of uncharacterized mutations and develops highly selective medicines for functionally & genomically defined cancer patients.
Nucleix is a liquid biopsy company that claims to be revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, its testing approach uses methylation-based identification for early-stage and recurring cancer detection. Its non-invasive EpiCheck platform delivers highly accurate and sensitive results, all while providing a seamless testing option for patients and the healthcare system.
Meetup with #CambridgeClinicalLaboratories, our partner for the UK, for the introduction of #Bladderepicheck® during the BAUS meeting December 9-10 at the Imperial War Museum, Duxford Airfield, Cambridge, UK pic.twitter.com/fAmvnbM3uu
— NUCLEIX (@NUCLEIX2) December 9, 2021
“Nucleix has incredible momentum as we enter 2022. We have the core methylation technology, the capital and a robust clinical program to advance Lung EpiCheck® for early lung cancer detection,” said Chris Hibberd, chief executive officer of Nucleix.
“EpiCheck is an ultra-sensitive technology for the detection of methylation changes and is compatible with both next-generation sequencing (NGS) and polymerase chain reaction (PCR) platforms. We are utilizing the NGS application of EpiCheck for deep discovery, to reveal new biomarkers for the early detection and monitoring of cancer. To demonstrate this capability, we conducted a side-by-side analysis which compared the EpiCheck NGS platform against conventional bisulfite approaches, using stage I lung cancer patients. While EpiCheck revealed many promising markers that are indicative of early-stage disease, the bisulfite approach only identified 1% of what EpiCheck detected. This result strengthens our belief that the EpiCheck technology sees biology that other approaches miss. We look forward to advancing research and product development in this area, both on our own and through collaborative efforts.”